A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
Latest Information Update: 21 May 2025
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Brain metastases
- Focus Adverse reactions
Most Recent Events
- 13 May 2025 Planned End Date changed from 31 Mar 2027 to 30 Mar 2028.
- 13 May 2025 Planned primary completion date changed from 31 Mar 2025 to 30 Mar 2028.
- 18 Nov 2024 Status changed from not yet recruiting to recruiting.